Protein Crystallography in Drug Discovery

· · · ·
· John Wiley & Sons
Carte electronică
278
Pagini
Evaluările și recenziile nu sunt verificate Află mai multe

Despre această carte electronică

Der auf Strukturen basierende Entwurf in der Wirkstoffentwicklung hat sich fast überall durchgesetzt. Dementsprechend kommt der Strukturaufklärung wichtiger Zielproteine durch Röntgenkristallographie eine wachsende Bedeutung auch im Pharmabereich zu. Hochaufgelöste Strukturen, die sich zum "rational drug design" einsetzen lassen, stellen einen hohen Wert dar und bilden oft die Basis für ein ganzes Entwicklungsprogramm.
Der Einsatz der Proteinkristallographie zur Wirkstoffentwicklung wird aus unterschiedlichen Blickwinkeln beleuchtet. Neben allgemeinen Strategien für wichtige Klassen von Zielproteinen wie Kinasen oder Proteasen werden konkrete Beispiele der aus der aktuellen Wirkstoffentwicklung beschrieben. Die Berichte stammen durchweg von den an der Entwicklung selbst beteiligten Forschern und bieten Informationen aus erster Hand, die hier erstmals veröffentlicht werden. Abschließend werden neueste technische Entwicklungen der Kristallographie vorgestellt, wie etwa die Entwicklung von Hochdurchsatzsystemen.
Mit seinem durchgehenden Praxisbezug wendet sich dieses Buch an alle Kristallographen, die Proteinstrukturen aufklären wollen und bietet eine wertvolle Grundlage für Anwender des strukturbasierten Wirkstoffdesigns.

Despre autor

Robert E. Babine has diverse drug discovery experience over the past 20 years and is presently the Director of Structural & Computational Chemistry at SPRL in Cambridge, Massachusetts. After receiving his Ph.D. in synthetic organic chemistry at Brown University he joined the medicinal chemistry group at Lederle Laboratories. During his 10 years at Lederle his research evolved into structure-based drug design, culminating in a project that discovered hydroxylaminepentanamide HIV protease inhibitors. Thereafter, he was in the medicinal chemistry group at Agouron Pharmaceuticals where he was involved in the early phase discovery of rhinovirus 3C protease inhibitors. After a 2-year stay at Eli Lilly he joined the new startup company SPRL in 2000.
******
Sherin S. Abdel-Meguid is Chief Scientific Officer and Founder of Suntory Pharmaceutical Research Laboratories (SPRL), a structure-based drug discovery company located in Cambridge, Massachusetts. He joined SPRL from SmithKline Beecham (SB) where he was Director of Macromolecular Sciences and Structural Biology, and director of the IL18, Herpes virus protease and CD28 programs. Prior to his work for SB, he was Head of Biophysical Sciences and Protein Engineering at Monsanto. At Monsanto, he built one of the first macromolecular crystallography groups in the pharmaceutical industry. He holds a Ph.D. in Physical Chemistry and M.S. and B.S. degrees in Biochemistry.

Evaluează cartea electronică

Spune-ne ce crezi.

Informații despre lectură

Smartphone-uri și tablete
Instalează aplicația Cărți Google Play pentru Android și iPad/iPhone. Se sincronizează automat cu contul tău și poți să citești online sau offline de oriunde te afli.
Laptopuri și computere
Poți să asculți cărțile audio achiziționate pe Google Play folosind browserul web al computerului.
Dispozitive eReader și alte dispozitive
Ca să citești pe dispozitive pentru citit cărți electronice, cum ar fi eReaderul Kobo, trebuie să descarci un fișier și să îl transferi pe dispozitiv. Urmează instrucțiunile detaliate din Centrul de ajutor pentru a transfera fișiere pe dispozitivele eReader compatibile.